Jarislowsky, Fraser Ltd’s AbbVie ABBV Stock Holding History

Jarislowsky, Fraser Ltd’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$20.6M	Buy	88,873 +90	+0.1%	+$18.3K	0.11%	76
2025 Q2	$16.5M	Sell	88,783 -3,510	-4%	-$652K	0.09%	79
2025 Q1	$19.3M	Sell	92,293 -6,935	-7%	-$1.35M	0.12%	78
2024 Q4	$17.6M	Sell	99,228 -130	-0.1%	-$23.9K	0.1%	79
2024 Q3	$19.6M	Sell	99,358 -175	-0.2%	-$32.7K	0.11%	80
2024 Q2	$17.1M	Sell	99,533 -32,145	-24%	-$5.32M	0.1%	80
2024 Q1	$24M	Sell	131,678 -11,954	-8%	-$2.06M	0.14%	77
2023 Q4	$22.3M	Buy	143,632 +547	+0.4%	+$79.7K	0.13%	76
2023 Q3	$21.3M	Sell	143,085 -333	-0.2%	-$48.9K	0.14%	74
2023 Q2	$19.3M	Sell	143,418 -2,967	-2%	-$435K	0.11%	80
2023 Q1	$23.3M	Sell	146,385 -4,301	-3%	-$658K	0.14%	72
2022 Q4	$24.4M	Sell	150,686 -200	-0.1%	-$30.7K	0.16%	71
2022 Q3	$20.3M	Sell	150,886 -700	-0.5%	-$100K	0.14%	75
2022 Q2	$23.2M	Sell	151,586 -675	-0.4%	-$103K	0.15%	73
2022 Q1	$24.7M	Sell	152,261 -2,825	-2%	-$410K	0.13%	77
2021 Q4	$21M	Sell	155,086 -26,290	-14%	-$3.11M	0.1%	81
2021 Q3	$19.6M	Sell	181,376 -2,850	-2%	-$326K	0.1%	81
2021 Q2	$20.8M	Sell	184,226 -5,495	-3%	-$619K	0.1%	78
2021 Q1	$20.5M	Sell	189,721 -1,150	-0.6%	-$123K	0.1%	75
2020 Q4	$20.5M	Buy	190,871 +50	+0%	+$4.8K	0.1%	74
2020 Q3	$16.7M	Sell	190,821 -2,375	-1%	-$224K	0.1%	78
2020 Q2	$19M	Sell	193,196 -7,925	-4%	-$698K	0.12%	75
2020 Q1	$15.3M	Sell	201,121 -19,825	-9%	-$1.69M	0.11%	77
2019 Q4	$19.6M	Sell	220,946 -3,333	-1%	-$277K	0.1%	77
2019 Q3	$17M	Sell	224,279 -7,990	-3%	-$548K	0.1%	80
2019 Q2	$16.9M	Sell	232,269 -6,387	-3%	-$502K	0.1%	79
2019 Q1	$19.2M	Sell	238,656 -6,609	-3%	-$541K	0.12%	77
2018 Q4	$22.6M	Sell	245,265 -1,575	-0.6%	-$139K	0.16%	73
2018 Q3	$19.2M	Sell	246,840 -3,509	-1%	-$333K	0.12%	80
2018 Q2	$23.2M	Sell	250,349 -5,453	-2%	-$533K	0.14%	78
2018 Q1	$24.2M	Sell	255,802 -3,925	-2%	-$431K	0.15%	78
2017 Q4	$25.1M	Buy	259,727 +283	+0.1%	+$26.7K	0.15%	76
2017 Q3	$23.1M	Buy	259,444 +1,840	+0.7%	+$140K	0.14%	78
2017 Q2	$18.7M	Sell	257,604 -3,700	-1%	-$249K	0.12%	82
2017 Q1	$17M	Sell	261,304 -2,384	-0.9%	-$150K	0.11%	89
2016 Q4	$16.5M	Buy	263,688 +540	+0.2%	+$33K	0.11%	90
2016 Q3	$16.6M	Sell	263,148 -1,019,960	-79%	-$66M	0.11%	91
2016 Q2	$72.6M	Buy	1,283,108 +1,020,489	+389%	+$62.2M	0.5%	49
2016 Q1	$15M	Buy	262,619 +33	+0%	+$1.84K	0.1%	94
2015 Q4	$15.6M	Sell	262,586 -94	-0%	-$5.41K	0.12%	91
2015 Q3	$14.3M	Buy	262,680 +4,400	+2%	+$286K	0.11%	89
2015 Q2	$17.4M	Sell	258,280 -2,900	-1%	-$189K	0.12%	87
2015 Q1	$15.3M	Sell	261,180 -19,490	-7%	-$1.18M	0.1%	88
2014 Q4	$18.4M	Sell	280,670 -1,126	-0.4%	-$71K	0.11%	83
2014 Q3	$16.3M	Sell	281,796 -15,210	-5%	-$844K	0.1%	91
2014 Q2	$16.8M	Sell	297,006 -500	-0.2%	-$26.2K	0.09%	89
2014 Q1	$15.3M	Sell	297,506 -5,337	-2%	-$270K	0.09%	90
2013 Q4	$16M	Buy	+302,843	New	+$14.9M	0.09%	90

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Jarislowsky, Fraser Ltd's ABBV Position: Q3 2025 in Review

Jarislowsky, Fraser Ltd increased its AbbVie (ABBV) stake by 0.1% in Q3 2025, buying an estimated $18.3K and bringing the position to 88,873 shares worth $20.6M. The position accounts for 0.11% of the portfolio, ranked #76.

Jarislowsky, Fraser Ltd first reported a position in ABBV in Q4 2013 and has held it in 48 quarters since. The position peaked at $72.6M in Q2 2016. 3,905 funds tracked by Wall St. Rank hold ABBV as of Q3 2025.

Jarislowsky, Fraser Ltd held 88,873 shares of AbbVie worth $20.6M as of Q3 2025.
Jarislowsky, Fraser Ltd bought 90 AbbVie shares in Q3 2025, an estimated $18.3K.
AbbVie made up 0.11% of Jarislowsky, Fraser Ltd's portfolio in Q3 2025, its #76 holding.
Jarislowsky, Fraser Ltd first reported a position in AbbVie in Q4 2013 and has held it in 48 quarters since.
Jarislowsky, Fraser Ltd's AbbVie position peaked at $72.6M in Q2 2016.
3,905 funds tracked by Wall St. Rank held AbbVie as of Q3 2025.

Based on Jarislowsky, Fraser Ltd's 13F filing for Q3 2025, filed 21 Oct 2025.